{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:16:55Z","timestamp":1791911815872,"version":"4.3.4"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"unspecified","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,1,5]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Early disease activity control with targeted therapies may improve long-term outcomes in axial spondyloarthritis (axSpA). Here, we evaluated the efficacy of upadacitinib in patients with axSpA with shorter versus longer symptom durations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SELECT-AXIS 1 and 2 studies enrolled patients with radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA) na\u00efve to biologic disease-modifying antirheumatic drugs (bDMARD-na\u00efve) and with an intolerance or inadequate response to bDMARD therapy. Patients were stratified by symptom duration (nr-axSpA: early vs established (\u22642\u2009vs &gt;2 years=Assessment of SpondyloArthritis international Society (ASAS) definition) and shorter vs longer (\u22645\u2009vs &gt;5 years); r-axSpA: \u22645\u2009vs &gt;5 years). Efficacy endpoints assessed through week 14 included the proportion of patients achieving Axial Spondyloarthritis Disease Activity Score and ASAS40 responses, among others. Across all endpoints, the efficacy of upadacitinib versus placebo was assessed by relative risk (RR), and the placebo-adjusted effect of upadacitinib between shorter versus longer symptom duration was assessed by the RR ratio.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 14, better responses were observed in patients treated with upadacitinib in all endpoints assessed compared with placebo, regardless of symptom duration. When comparing patients with early\/shorter versus established\/longer symptom durations, for all measures assessed, no statistically significant differences were observed except for the change from baseline in high-sensitivity C-reactive protein in the nr-axSpA group, with a better response in early disease (difference \u20138.2, 95%\u2009CI \u201314.9 to \u20131.6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Regarding short-term outcomes, both subgroups of patients (shorter axSpA symptom duration (\u22642 years) and longer symptom duration (&gt;2 years)) achieved comparable results when treated with upadacitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03178487\">NCT03178487<\/jats:ext-link> (SELECT-AXIS 1) and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04169373\">NCT04169373<\/jats:ext-link> (SELECT-AXIS 2).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-005110","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:06:03Z","timestamp":1741115163000},"page":"e005110","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03178487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03178487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario La IdiPAZ, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium"},{"name":"VIB Center for Inflammation Research, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-6686","authenticated-orcid":false,"given":"Percival Degrava","family":"Sampaio-Barros","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade do Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4827","authenticated-orcid":false,"given":"Andrew J K","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[{"name":"Monash University & Emeritus Research, Cabrini Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumik","family":"Parikh","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Stigler","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025090312274279000_11.1.e005110.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2025090312274279000_11.1.e005110.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"key":"2025090312274279000_11.1.e005110.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"2025090312274279000_11.1.e005110.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105603","article-title":"Looking through the window of opportunity in axial spondyloarthritis?","volume":"90","author":"Benavent","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025090312274279000_11.1.e005110.5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jbspin.2019.04.006","article-title":"Structural progression in axial spondyloarthritis","volume":"87","author":"Aouad","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2025090312274279000_11.1.e005110.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025090312274279000_11.1.e005110.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202698"},{"key":"2025090312274279000_11.1.e005110.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203075"},{"key":"2025090312274279000_11.1.e005110.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.38070"},{"key":"2025090312274279000_11.1.e005110.10","doi-asserted-by":"publisher","DOI":"10.1186\/ar4561"},{"key":"2025090312274279000_11.1.e005110.11","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/keac532","article-title":"Treating spondyloarthritis early: does it matter? Results from a systematic literature review","volume":"62","author":"Capelusnik","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312274279000_11.1.e005110.12","doi-asserted-by":"crossref","first-page":"iv25","DOI":"10.1093\/rheumatology\/keaa472","article-title":"Axial spondyloarthritis 10 years on: still looking for the lost tribe","volume":"59","author":"Barnett","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312274279000_11.1.e005110.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152032","article-title":"How is early spondyloarthritis defined in the literature? Results from a systematic review","volume":"55","author":"Benavent","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312274279000_11.1.e005110.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224232"},{"key":"2025090312274279000_11.1.e005110.15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"2025090312274279000_11.1.e005110.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608"},{"key":"2025090312274279000_11.1.e005110.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"2025090312274279000_11.1.e005110.18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"van der Heijde","year":"2022","journal-title":"RMD Open"},{"key":"2025090312274279000_11.1.e005110.19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/annrheumdis-2022-eular.164","article-title":"OP0034 IXEKIZUMAB improves signs, symptoms, and quality of life in patients with axial SpA irrespective of disease duration: results from the COAST-V, COAST-W and COAST-X trials","volume":"81","author":"Navarro-Comp\u00e1n","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090312274279000_11.1.e005110.20","unstructured":"Kay J , Gensler L , Deodhar A , et al . Earlier treatment of non-radiographic axial spondyloarthritis with certolizumab pegol results in improved clinical and patient-reported outcomes. Arthritis Rheumatol 2019;71 (Suppl 10):936."},{"key":"2025090312274279000_11.1.e005110.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145995"},{"key":"2025090312274279000_11.1.e005110.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.33465"},{"key":"2025090312274279000_11.1.e005110.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"2025090312274279000_11.1.e005110.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.21054"},{"key":"2025090312274279000_11.1.e005110.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.30100"},{"key":"2025090312274279000_11.1.e005110.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1492-5"},{"key":"2025090312274279000_11.1.e005110.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312274279000_11.1.e005110.28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000057","article-title":"Rheumatoid arthritis treatment: the earlier the better to prevent joint damage","volume":"1","author":"Monti","year":"2015","journal-title":"RMD Open"},{"key":"2025090312274279000_11.1.e005110.29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2019-eular.2829","article-title":"FRI0388 secukinumab improves health-related quality of life in patients with ankylosing spondylitis, irrespective of time since first diagnosis: pooled results from the secukinumab phase 3 trial program","volume":"78","author":"Deodhar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312274279000_11.1.e005110.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2025090312274279000_11.1.e005110.31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/annrheumdis-2024-eular.2352","article-title":"POS0799 efficacy of BDMARDS in early versus established disease in axial spondyloarthritis: a meta-analysis of randomized trials","volume":"83","author":"Benavent","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090312274279000_11.1.e005110.32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.873"},{"key":"2025090312274279000_11.1.e005110.33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2024-eular.5127","article-title":"OP0132 treat-to-target approach allows to induce sustained clinical remission in over 60% of patients with early axial spondyloarthritis","volume":"83","author":"\u0141ukasik","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:27:51Z","timestamp":1756927671000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,4]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/rmdopen-2024-005110"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005110","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}